Sr Clinical Science Lead
GSK, Wavre, Belgium, Belgium
Disclosure(s): GSK: Salary as GSK employee with stock options, Stocks/Bonds (Public Company)
Professor Corinne Vandermeulen is a medical doctor by training, with additional qualifications as a preventive medicine in children. In 2009, she obtained her PhD in Medical Sciences based on research in vaccinology at KU Leuven.
Prior to joining industry in 2021, she was the head of the Leuven University Vaccinology Center at KU Leuven, Belgium were her research covered the immunological and epidemiological evaluation of vaccine preventable diseases in different populations (healthy individuals and the chronically ill), health psychology background to vaccination (vaccine hesitancy), seroprevalence studies of vaccine-preventable infectious diseases, as well as the preclinical research trajectory of new vaccines. Finally, she is also a principal investigator in over 50 clinical trials of new vaccines in different age groups as well as investigator in >30 phase I clinical trials. Corinne Vandermeulen was also a member of the Permanent Working Group on Vaccination of the High Health Council, the Flemish Vaccination vaccination council. She was a Board member of Flanders Vaccine and in the Steering Committee of the FAMHP's spearhead domain Vaccination.
In 2021, she joined GSK as a sr Clinical Science Lead where she has been responsible for different trials in the at-increased risk population with Arexvy, leading to an updated indication for Arexvy for people 50-59yoa at increased risk for severe RSV disease.